SLIT-ROBO Rho GTPase-activating protein 2 (SRGAP2)

SLIT-ROBO Rho GTPase-activating protein 2 (SRGAP2) is a cytoplasmic protein characterized by F-BAR, RhoGAP, and SH3 domains, which mediate membrane association, cytoskeletal remodeling, and protein–protein interactions[1][5]. SRGAP2 is primarily involved in the development of the nervous system by regulating neuronal migration, differentiation, and synaptic maturation. It acts as an inhibitor of cell migration and controls membrane protrusions by binding to the plasma membrane at sites of cell protrusion, where its RhoGAP activity inactivates small GTPases (Rac1 and CDC42), leading to local actin cytoskeleton breakdown and retraction of membrane protrusions[1][5]. SRGAP2 plays a crucial role in synaptic development by regulating both excitatory and inhibitory synapse maturation and restricting their density via its interaction with postsynaptic scaffolding proteins like Homer1 (excitatory) and Gephyrin (inhibitory), and through its Rac1-GAP activity[3][5]. Human-specific paralogs (SRGAP2B, SRGAP2C) antagonize the ancestral SRGAP2 function, thereby enhancing synaptic density, prolonging synaptic development, and likely contributing to cortical expansion and higher cognitive functions in humans[1][2][4][5]. SRGAP2 may also participate in the development of certain cancers, such as colorectal cancer[2][6]. Currently, there are no known drug interactions, specific mechanisms of pharmacologic modulation, established biomarkers, or major safety concerns directly associated with SRGAP2 as a therapeutic target. While it is of significant biological and evolutionary interest, it is not a direct therapeutic target at present[2][5][6].

Other names

SLIT-ROBO Rho GTPase activating protein 2ARHGAP34FNBP2KIAA0456SRGAP2AsrGAP2Formin-binding protein 2Rho GTPase-activating protein 34